Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations

The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.

Previous post AMD’s AI story has lost some shine. Can earnings brighten the picture?
Next post Pfizer, Genmab get full FDA approval for cervical-cancer drug